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Background: PHACE is a neurocutaneous syndrome associated with: Posterior fossa brain malformations, large
“segmental” facial hemangiomas, arterial cerebrovascular-, cardiovascular-, and eye anomalies.
Case vignette: We are reporting a girl with PHACE syndrome. The patient had a congenital right-sided facial
hemangioma with plaque-morphology. At age 11 years and 2 months she presented with short stature, markedly
decreased growth velocity and signs and symptoms suggestive of hypothyroidism. Magnetic Resonance Imaging
(MRI) of the brain revealed complex structural and cerebrovascular arterial anomalies, including an empty sella.
Testing of pituitary function revealed multiple pituitary dysfunctions, including absolute growth hormone
deficiency, hypogonadotropic hypogonadism, central hypothyroidism, and secondary adrenal insufficiency.
Conclusions: This case suggests the necessity to screen all patients with PHACE syndrome and intracranial
malformations for pituitary dysfunction at regular intervals.
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Neurocutaneous syndromeBackground
PHACE syndrome (OMIM 606519) is a neurocutaneous
syndrome first described by Frieden et al. in 1996 [1].
PHACE syndrome refers to the association of a large,
segmental hemangioma, associated with one or more of
the following features: posterior fossa brain malforma-
tions (e.g. Dandy-Walker-complex, cerebellar hypoplasia
or atrophy, and dysgenesis or agenesis of vermis), arter-
ial cerebrovascular anomalies, cardiovascular anomalies,
and eye anomalies. The etiology and pathogenesis are
unknown. Potential comorbidities are mainly complica-
tions of cerebral and cerebrovascular anomalies and in-
clude seizures and ischemic strokes [2,3]. To date, a
total of approximately 300 patients with PHACE syn-
drome are reported in the literature. Contributions range
from case reports and smaller case series with e.g 25 [2]
and 12 [4] patients, to larger series with 130 [3], 70 [5]
and 43[1] patients respectively.* Correspondence: martin.wabitsch@uniklinik-ulm.de
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reproduction in any medium, provided the orTo date, a total of three patients with PHACE syn-
drome and congenital pituitary dysfunctions have been
described. Poindexter et al. reported a patient with con-
genital panhypopituitarism and cerebral and cardiovas-
cular anomalies diagnosed at age 13 months [6]. Metry
et al. reported a patient with ocular coloboma, partial
empty sella, and isolated growth hormone (GH) defi-
ciency [2]. Merheb at al reported a 16 year old patient
with central hypothyroidism and growth hormone defi-
ciency [7]. Hypogonadotropic hypogonadism was sus-
pected but not confirmed.
Here we report a case of PHACE syndrome and hypo-
pituitarism that appears to be acquired, an association
that is not previously described.
Case presentation
The 11 years and 2 months old girl presented to the
pediatric endocrinology department for evaluation of
short stature . After normal longitudinal growth in in-
fancy, the patient’s height SDS dropped from −1,67 SDS
to −3.23 SDS between the ages of 2.5 and 4.5 years. Sub-
sequently, she resumed normal height velocity, and
height SDS at 10.5 years was preserved at −2.96. At
presentation, height SDS was −3.10, weight SDS −2.38Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The midparental height SDS was 0.59.
Central hypothyroidism had been diagnosed 4 months
before presentation. The girl is of normal intelligence,
her school achievement is above average.
As far as we can determine retrospectively, there was no
clinical suspicion of hypoglycemia during the newborn
period. There was no history of severe illness. Febrile
infections were tolerated well and could all be treated at
home.
The patient had a history of a congenital right-sided
facial hemangioma of plaque-morphology (Figure 2).
This was treated in infancy with interferone- followed by
laser therapy. The clinical examination revealed a pre-
pubertal stage (Tanner PH1, B1).
Laboratory studies
Because of the described empty sella on MRI, compre-
hensive endocrine function testing was performed.
Reference ranges are given in parentheses.
 The GnRH test showed central hypogonadism
(Table 1). Estradiol was undetectable (<5 ng/l) until
treatment with estradiolvalerate was initiated.
 A diurnal profile of cortisol incretion was not
obtainable, but repeated measurements of ACTH
and serum cortisol after an overnight fast showed
persistently low levels for both parameters, with a
peak cortisol level of 2.7 μg/dl (6.2-19.4), and a peak





















































Figure 1 Patient’s Growth Chart. Measured height of the patient before
percentiles according to Prader et al., 1989 [8].cortisol excretion was low with 4,4 μg/d (36.0-137.0),
and DHEAS was low with 18.1 μg/dl (33.9-280.0).
 Thyroid stimulating hormone (TSH) levels never
exceeded 0.024 mIU/l (reference range 0.51-4.3),
supporting the diagnosis of central hypothyroidism.
Free thyroid hormone (fT4) levels were normal on
levothyroxine supplementation.
 Arginine stimulation test, performed twice on
separate days, revealed absolute growth hormone
deficiency (see Table 1). IGF-1 and IGFBP-3 were
normal initially, but decreased before starting GH
therapy 9 months after the initial presentation to
25 ng/ml (122–155) and 2460 ng/ml (2600–8100)
respectively.
In summary, our patient suffered from hypogonado-
tropic hypogonadism, secondary adrenal insufficiency,
central hypothyroidism and absolute growth hormone
deficiency.Imaging studies
MRI of the brain confirmed the findings of complex struc-
tural cerebral- and cerebrovascular arterial anomalies with
cerebellar dysplasia on the right side, deformation and dis-
location of the brain stem, and aplasia of the right carotid
(Figure 3). The empty sella (Figure 4) appeared to be
caused by dorsal displacement of the infundibulum by ara-
chnoidal cysts, which were stable in size over the course























































and after starting GH substitution is plotted on reference height
Figure 2 Picture of the Patient. Photography of the patient in
infancy before treatment of the haemangioma. At this stage, PHACE
syndrome could already have been suspected due to the typical
finding of a segmental hemangioma.
Figure 3 Arachnoidal cysts. MRI Scan of the brain. Coronar,
T2-weighted. Cerebellar dysplasia is seen on the right side. The
arrow indicates a large arachnoidal cyst.
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sis was identified.
To rule out further organ involvement, an echocardi-
ography and electrocardiography, as well as an abdom-
inal ultrasound were performed and were unremarkable.
The radiologic bone age of the left hand was 4 years
delayed according to the standards of Greulich and
Pyle.
Treatment
We initiated substitution of hydrocortisone at 10 mg/
m2/d p.o. immediately and GH treatment with 25 μg/
kg/d s.c. after 9 months (Patient aged 11 years and
11 months). The delay in starting GH treatment was
due to the patient's intense fear of injections and
therefore reluctance of the family to start treatment.
In the absence of spontaneous pubertal development,Table 1 Results of endocrine function testing
0 min 30 min 45 min 60 min 120 min
GnRH test LH IU/l < 0.1 <0.1
FSH IU/l 0.24 0.54
argininetest 1 HGH μg/l 0.07 <0.05 0.05 <0.05
argininetest 2 HGH μg/l 0,09 0,13 0,13 <0,05
A GnRH test was performed by administering 3.5 μg/kg GnRH by intravenous
injection. Blood samples were taken at baseline and 45 minutes after GnRH
application. Two independent arginine tests were performed by applying
l-argininehydrochloride 21 % 0.5 g /kg. Blood samples were taken at start and
after 30, 60 and 120 minutes.Estradiolvalerate 0,3 mg/d was started at the age of
13 years and increased to 0,6 mg/d after 6 months at
pubertal stage B2, PH2. The treatment with thyroxine
was continued.
The patient is now 13 years and 6 months old. Her
height has reached the 3. Percentile (−2,5 SDS)(Figure 1)
and stage of puberty is Tanner B2, PH2.Figure 4 Empty sella. MRI Scan of the brain. Sagittal, T2-weighted.
The arrow indicates the empty sella.
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Hypogonadotropic hypogonadism, secondary adrenal in-
sufficiency, central hypothyroidism and absolute growth
hormone deficiency diagnosed at the age of 11 years led
to a comprehensive diagnostic work-up revealing the
diagnosis of PHACE syndrome. While acquired hypo-
pituitarism has not yet been reported in association with
PHACE syndrome, there are several factors that make
congenital hypopituitarism unlikely in our patient:
The patient had normal growth velocity from 4.5 to
10 years of life. Thus, while there may have been some
degree of growth hormone insufficiency early on, abso-
lute congenital growth hormone deficiency seems un-
likely. Further evidence of intact growth hormone- and
adrenal axes in early childhood includes the absence of
symptomatic hypoglycemia during the newborn period,
the absence of episodes of severe illness, and the ability
to tolerate febrile infections well with no need for hospi-
talizations. Congenital hypothyroidism can essentially be
ruled out by the patient’s normal intelligence and aca-
demic achievement.
One possible explanation for the acquired hypopituit-
arism is that the arachnoidal cyst located in the area of
the sella may have caused chronic pressure on the ade-
nohypophysis, leading to a progressive loss of function.
As reported in the literature, intracranial cysts can cause
a wide spectrum of endocrine insufficiencies [9]. An-
other potential mechanism causing a more acute onset
of pituitary dysfunctions might have been a thrombo-
embolic event with infarction of the adenohypophysis.
However, no case of endocrine dysfunction after a
thrombembolic event has been reported in the literature,
and the patient has no clinical correlates and no MRI
evidence of a thrombembolic event.
We conclude that screening of pituitary functions in
patients with PHACE syndrome and intracranial malfor-
mations is recommendable both at diagnosis and during
follow up.
We suggest yearly follow up including: Anthropometric
measurements, clinical assessment of pubertal develop-
ment, and laboratory evaluations of TSH, fT4, ACTH and
Cortisol. Decreased height velocity or delayed puberty
should warrant further diagnostic evaluation.Consent
Written informed consent was obtained from the patient
for publication of this Case report and the accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.Competing interests
The authors declare that they have no competing interests.Author details
1Department of Pediatrics and Adolescent Medicine, Division of Pediatric
Endocrinology and Diabetes, University Hospital of Ulm, Eythstr. 24, Ulm
D-89075, Germany. 2Pediatric Neurology Department, University Hospital of
Ulm, Eythstr. 24, Ulm D-89075, Germany. 3Department of Pediatrics and
Adolescent Medicine, Division of Pediatric Endocrinology and Diabetes,
University Hospital of Ulm, Eythstr. 24, Ulm D-89075, Germany.
Authors’ contributions
FD diagnosed the patient and drafted the manuscript. CD revised the
manuscript. BL revised the manuscript. HB made substantial contributions to
the process of diagnosing the patient. MW has revised the manuscript and
gave final approval of the version to be published. All authors read and
approved the final manuscript.
Received: 13 January 2012 Accepted: 30 June 2012
Published: 30 June 2012
References
1. Frieden IJ, Reese V, Cohen D: PHACE syndrome: the association of
posterior fossa brain malformations, hemangiomas, arterial anomalies,
coarctation of the aorta and cardiac defects, and eye abnormalities. Arch
Dermatol 1996, 132:307–311.
2. Metry DW, Haggstrom AN, Drolet BA, Baselga E, Chamlin S, Garzon M, Horii K,
Lucky A, Mancini AJ, Newell B, Nopper A, Heyer G, Frieden IJ: A prospective
study of PHACE syndrome in infantile hemangiomas: demographic
features, clinical findings, and complications. Am J Med Genet 2006,
140A:975–986.
3. Metry DW, Dowd CF, Barkovich AJ, Frieden IJ: The many faces of PHACE
syndrome. J Pediatr 2001, 139:117–123.
4. Bracken J, Robinson I, Snow A, Watson R, Irvine AD, Rea D, Phelan E: PHACE
syndrome: MRI of intracerebral vascular anomalies and clinical findings
in a series of 12 patients. Pediatr Radiol 2011, 41(9):1129–1138.
5. Hess CP, Fullerton HJ, Metry DW, Drolet BA, Siegel DH, Auguste KI, Gupta N,
Haggstrom AN, Dowd CF, Frieden IJ, Barkovich AJ: Cervical and intracranial
arterial anomalies in 70 patients with PHACE syndrome. Am J Neuroradiol
2010, 31(10):1980–1986.
6. Poindexter G, Metry DW, Barkovich AJ, Frieden IJ: PHACE syndrome with
intracerebral hemangiomas, heterotopia, and endocrine dysfunction.
Pediatr Neurol 2007, 36(6):402–406.
7. Merheb M, Hourani R, Zantout MS, Azar ST: Endocrine dysfunction in a
patient with PHACE syndrome, including port-wine stain of the right
periorbital area. Endocr Pract 2010, 16:255–259.
8. Prader A, Largo RH, Molinari L, Issler C: Physical growth of Swiss children
from birth to 20 years of age. First Zurich longitudinal study of growth
and development. Helv Paediatr Acta Suppl 1989, 52:1–125.
9. Savas Erdeve S, Ocal G, Berberoglu M, Siklar Z, Hacihamdioglu B, Evliyaoglu O,
Fitoz S: The endocrine spectrum of intracranial cysts in childhood and
review of the literature. J Pediatr Endocrinol Metabol 2011, 24(11–12):867–875.
doi:10.1186/1687-9856-2012-20
Cite this article as: Denzer et al.: A case of phace syndrome and
acquired hypopituitarism?. International Journal of Pediatric Endocrinology
2012 2012:20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
